DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Rimegepant
Rimegepant
Pharmacokinetics, Pharmacodynamics and Drug
Nurtec ODT (Rimegepant)
VYEPTI™ (EPTINEZUMAB) Policy Number: CSLA2020D0090A Effective Date: TBD
Rimegepant in the Treatment of Migraine
CGRP Signaling Via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia
Nurtec® ODT Common Name: Rimegepant Tablet, Orally Disintegrating PDL Category: CGRP Inhibitors
Comparative Efficacy and Safety of Rimegepant Versus Ubrogepant and Lasmiditan for Acute Poster No
Preferred Drug List
Pharmacokinetics, Pharmacodynamics
Calcitonin Gene-Related Peptide Receptor (CGRP) Antagonists, Acute
Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
Migraine Management
2020 Aetna Standard Plan
HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use NURTEC ODT Safely and Ef
Stembook 2018.Pdf
CGRP and Headache: a Brief Review
Acute Migraine Treatment: Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist Medical Policy No
E-Binder March 2020
Top View
Utah Medicaid Dur Report June 2020 Cgrp Antagonists
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Potential for Treatment Benefit of Small Molecule CGRP Receptor
PDL)/Non-Preferred Drug List (NPDL
Agents for Migraine – Nurtec ODT (Rimegepant), Ubrelvy (Ubrogepant) P&T Approval Date 10/2020; 2/2021 Effective Date 4/1/2021; Oxford: 5/1/2021
Medicaid List of Covered Drugs (Formulary)
TEXAS MEDICAID Clinical Edit Prior Authorization Rimegepant (NURTEC)
PDCO Agenda of the 26-29 January 2021 Meeting
Nurtec ODT (Rimegepant) Quantity Override
FEP 5 Tier Rx Drug Formulary (607) Standard Option
Making Migraine Treatment a Priority
Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
INP104 MAIC AHS 2021 Poster
CLINICAL REVIEW(S) Clinical Review Laura Jawidzik, MD NDA (B) (4) and 212728 Rimegepant (B) (4)
Preferred Drug List (PDL)
Health Plan Insights
Blocking CGRP in Migraine Patients – a Review of Pros and Cons
SUTTER HEALTH PLUS FORMULARY Drug List for HMO Members – Effective September 1, 2021
Anti‐Migraine Calcitonin Gene–Related Peptide Receptor
Calcitonin Gene-Related Peptide Receptor (CGRP) Antagonists (Acute Treatment)
Alaska Medicaid Preferred Drug List (PDL)
Rimegepant Is Effective for the Acute Treatment of Migraine in Patients
PDCO Minutes of the 26-29 January 2021 Meeting
Clinical Pharmacology and Biopharmaceutics Review(S)
FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
(KPIC) Point-Of-Service (POS) Drug Formulary
Hereditary Angioedema
Acute Treatment Benefit from Oral CGRP Receptor Antagonist and Monoclonal Antibody Combination: Poster No
Table of Contents
Rxfiles Chart Updates – 13Th Edition – DRUG, Disease, Trials INDEX – Generic Name / TRADE NAME ©
CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine
EFFECTIVE 01/01/2021 Version 2021.1A
2021 Formulary Kaiser Permanente a TRICARE® Prime Option
Optumrx 2020 Premium Prior Authorization List
PA Drug Name Generic Name PA Summary Name Epaned Enalapril
212728Orig1s000 SUMMARY REVIEW
Rimegepant (Nurtec) Criteria for Use March 2021
Pharmacologic Updates in the Management of Acute Migraines and Migraine Prevention
Oxford Policy Update Bulletin: May 2020
(Aimovig™), Galcanezumab (Emgality®), Fremanezumab (Ajovy®) EOCCO POLICY Policy Type: PA/SP Pharmacy Coverage Policy: EOCCO025
401 Pharmacology Update 2021
Oral CGRP Antagonists NOTICE